-

Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

LYON, France--(BUSINESS WIRE)--Brenus Pharma has successfully joined the Paris Saclay Cancer Cluster (PSCC), the first national Onco-cluster. This membership positions Brenus at the heart of the European initiative to accelerate and valorize innovation in oncology.

As the inaugural beneficiary of the France 2030 NextGenerationEU program, PSCC represents a paradigm shift in the pace and anticipation of oncological advancements. Dedicated to improving the predictability and efficiency of cancer research, PSCC fosters collaboration within scientific, medical, and industrial communities, providing privileged access to cutting-edge resources.

Located in Grand Paris, PSCC brings together a diverse community of 80 members from 9 different nationalities. Chaired by Professors Éric Vivier and Solange Peters, PSCC aims to promote French research and the transfer of innovations to the European and global levels in the field of oncology.

Focused on transforming the treatment of solid tumor cancers, Brenus Pharma stands out with its patented platform of anticancer vaccine immunotherapies. By joining PSCC, Brenus Pharma will have access to technological and biological platforms, expertise, and collaborative resources to accelerate its advancements while contributing to the collective ambition of the ecosystem.

For more information: www.brenus-pharma.com;https://www.parissaclaycancercluster.org/

Contacts

BRENUS
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Industry:

Brenus Pharma

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)
Hashtags
#Biotech
#Clinical
#Healthcare
#Immunotherapy
#PSCC

Contacts

BRENUS
contact@brenus-pharma.com
+ 33 (0)7 87 76 87 72

Social Media Profiles
Follow Brenus Pharma
More News From Brenus Pharma

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during do...

Brenus Pharma Expands Its Global Scientific Advisory Board With Us Immuno-Oncology Expert Prof. Olivera J. Finn

LYON, France & PITTSBURGH--(BUSINESS WIRE)--Brenus Pharma, a clinical-stage biotechnology company developing first-in-class in vivo immunotherapies for solid tumors, announced the appointment of Olivera J. Finn, Distinguished Professor at the University of Pittsburgh School of Medicine, to its Scientific Advisory Board (SAB). This strategic addition strengthens Brenus’ international SAB as the company advances its proprietary Stimulated Ghost Cell (SGC) platform and lead candidate STC-1010 towa...

Brenus Pharma Announces First Patients Dosed in its First-in-Human Trial Evaluating STC-1010, a Next-Generation Immunotherapy

LYON, France--(BUSINESS WIRE)--Brenus Pharma today announced that first patients have been successfully dosed in its first-in-human clinical trial evaluating STC-1010, the company’s lead in vivo immunotherapy candidate developed through its proprietary off-the-shelf platform. Three patients have already been enrolled in the study. The first completed eight weeks of treatment with no adverse events attributed to the investigational therapy. This trial targets patients with unresectable, locally...
Back to Newsroom